Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients

Completed

• Conditions: Diabetes Mellitus; Atrial Fibrillation (AF)

• Registration Number: NCT06951737
• Lead Sponsor: Bursa Postgraduate Hospital

Brief Summary

Consecutive DCCV was performed until to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who did not use SGLT-2 inhibitors). Patients defined as SGLT-2 inhibitor user group and control group. The two groups were monitored for AF recurrence on the first day, then at one, three, and six months after CV.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-10-02
• Primary Completion: 2024-04-02
• Study Completion: 2024-10-02
• Status Verified: 2025-04
• Study First Submitted: 2025-04-20
• Study First Submitted QC: 2025-04-23
• Last Update Submitted: 2025-04-23
• Study First Posted: 2025-04-30
• Last Update Posted: 2025-04-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• patients > 18 years and < 90 years, a patient diagnosed with DM who underwent electrical cardioversion due to AF and was restored to sinus rhythm

Exclusion Criteria

• patient who are not suitable for anticoagulant use, have thyroid dysfunction, glomerular filtration rate ≤ 25 ml/min/1.73 m², patients whose sinus rhythm cannot be achieved with electrical cardioversion, malignancy patients, patients with acute or chronic inflammatory disease, patients with peripheral artery disease, patients with pacemakers, patients with advanced valve stenosis or insufficiency, patients who have had coronary bypass surgery, patients with percutaneous or surgical bioprosthesis or metallic valve surgery.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Atrial fibrillation recurrence	six month

Trial Locations

Locations (1)

Bursa Yüksek İhtisas Hastanesi; 🇹🇷 Bursa, Turkey